Latest Content

Imfinzi Plus Chemo May Improve Event-Free Survival in Gastric, GEJ Cancers

March 8th 2025, 3:00pm

By Alex Biese

Article

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric and gastroesophageal junction cancers.

177Lu-edotreotide May Delay Progression in Neuroendocrine Tumor Subset

March 7th 2025, 10:00pm

By Spencer Feldman

Article

177Lu-edotreotide shows potential to extend progression-free survival in patients with grade 1 or 2 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

The Dawn of a New Era in Cancer Treatment

March 7th 2025, 8:00pm

By Mike Hennessy Jr.

Article

New advancements in cancer treatment are reducing the need for radical surgeries, offering organ-sparing therapies and enhancing survivorship care and support for patients.

Challenging Cancer Stereotypes While Living with Follicular Lymphoma

March 7th 2025, 6:00pm

By Karen Cohn

Article

Living with follicular lymphoma, I challenge common misconceptions about cancer, highlighting the unique and varied experiences of patients with cancer.

BRCA1/2 Mutations May Associate With Better Chemo Response in TNBC

March 7th 2025, 4:00pm

By Alex Biese

Article

Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in patients with BRCA1/2 mutations.

Calquence Combo May Improve Outcomes in Chronic Lymphocytic Leukemia

March 7th 2025, 2:00pm

By Spencer Feldman

Article

Calquence plus Venclexta with or without Gazyva significantly improved progression-free survival in patients with untreated CLL.

Presurgical Opdivo Plus Yervoy Has Potential Clinical Benefit in NSCLC

March 6th 2025, 10:00pm

By Alex Biese

Article

Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical benefits versus chemotherapy.

How the FDA Approval of Imfinzi Advances Small Cell Lung Cancer Treatment

March 6th 2025, 8:00pm

By Alex Biese

Video

The FDA has approved Imfinzi for some adults with limited-stage small cell lung cancer.

FDA Approval of Ensacove Adds to the Toolkit for ALK-Positive NSCLC

March 6th 2025, 8:00pm

By Alex Biese

Video

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer.

What the FDA Approval of Bizengri Means for Patients With NRG1-Positive NSCLC

March 6th 2025, 8:00pm

By Alex Biese

Video

The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 gene fusion.

What’s On the Horizon for Small Cell Lung Cancer Research?

March 6th 2025, 8:00pm

By Darlene Dobkowski, MA

Video

On the heels of two FDA approvals in lung cancer treatments, what innovations are next?

Looking For The Light After MDS

March 6th 2025, 6:00pm

By Jane Biehl Ph.D.

Article

As a cancer survivor, I talk about where to look for the light when in utter darkness.

A Patient’s Journey With Colon Cancer and Her Advocacy Mission

March 6th 2025, 5:34pm

By Spencer Feldman

Video

Melissa Ursini, diagnosed with stage 2 colon cancer, shares her journey to raise awareness and encourage early detection through colonoscopies.

What Patients Need to Know About Appealing Insurance Denials

March 6th 2025, 4:42pm

By Alex Biese

Article

The CEO of Triage Cancer discussed the “best-kept secret” of the health care system in an interview with CURE.

Artificial Intelligence Enhances Polyp Detection in Colorectal Cancer

March 6th 2025, 2:01pm

By Ryan Scott

Article

Artificial intelligence aids in polyp detection, enhancing colonoscopy effectiveness and reducing the risk of colorectal cancer progression in patients.